Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study (Q42647881)

4 November 2017

Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study (English)

1 reference

multicenter clinical trial

4 November 2017

0 references

author name string

C Stefanutti

1

1 reference

4 November 2017

G D'Alessandri

2

1 reference

4 November 2017

G Russi

3

1 reference

4 November 2017

G De Silvestro

4

1 reference

4 November 2017

M G Zenti

5

1 reference

4 November 2017

P Marson

6

1 reference

4 November 2017

D Belotherkovsky

7

1 reference

4 November 2017

A Vivenzio

8

1 reference

4 November 2017

S Di Giacomo

9

1 reference

4 November 2017

1 December 2009

1 reference

Atherosclerosis. Supplements

4 November 2017

1 reference

4 November 2017

10

1 reference

4 November 2017

5

1 reference

4 November 2017

89-94

1 reference

Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

The importance of the relation between lipoprotein(a) and lipids for development of atherosclerosis and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

State of the art of lipid apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Recommendations for the use of LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

26 years of LDL--apheresis: a review of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Comparison of different Lp (a) elimination techniques: a retrospective evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

Italian Multicenter Study on Low-Density Lipoprotein Apheresis: retrospective analysis (2007).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2809%2971819-7

7 January 2021

10.1016/S1567-5688(09)71819-7

Identifiers

DOI

1 reference

4 November 2017

1 reference